Latest News - Regeneron Pharmaceuticals
Top Corporates Hub
Regeneron Pharmaceuticals
AstraZeneca’s gMG drug fails to fend off rivals despite Phase III win
31.10.2025 12:37
While gefurulimab offered significant improvements to MG-ADL scores, it was bested by a variety of pipeline and marketed gMG drugs.
Dupixent® (dupilumab) Wins Prestigious 2025 Prix Galien USA Best Biotechnology Product Award
31.10.2025 11:00
Award recognizes the groundbreaking science of Dupixent and its transformational impact on multiple rare and common allergic and atopic conditions First and only therapy to specifically target the IL-4 and IL-13 signaling pathway, a key driver of type 2 inflammation that contributes to multiple conditions TARRYTOWN, N.Y., Oct. 31, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that Dupixent® (dupilumab) has been recognized as the “Best Biotechnology Produ
JW Therapeutics and Regeneron Expand Strategic Collaboration Agreement to Advance TCR-T Cell Therapy Development and Maximize Global Platform Potential
31.10.2025 09:38
JW Therapeutics (HKEx: 2126), an independent and innovative biotechnology company focusing on developing, manufacturing and commercializing cell immunotherapy products, announced the execution of an Amendment to its strategic collaboration agreement with Regeneron Pharmaceuticals, Inc. ("Regeneron"), a leading global biotechnology company. This amendment not only signifies a major upgrade in long-term partnership between the two companies, but also marks the beginning of a new phase of collabora
Opko Health Inc.’s (OPK) ModeX Therapeutics Announces License and Collaboration Agreement With Regeneron Pharmaceuticals
31.10.2025 03:29
Opko Health Inc. (NASDAQ:OPK) is one of the best stocks under $5 with highest upside potential. ModeX Therapeutics Inc., an Opko Health Inc. (NASDAQ:OPK) company, announced on October 29 a license and collaboration agreement with Regeneron Pharmaceuticals Inc. for the development and discovery of multispecific antibodies for a number of therapeutic indications of mutual interest. […]
What Catalysts Are Driving the Changing Narrative for Regeneron?
30.10.2025 13:14
Regeneron Pharmaceuticals recently saw its Fair Value price target increased from $722.20 to $735.72. This change comes on the heels of new earnings results and momentum within its drug pipeline. The revision reflects updated analyst models that weigh the strength of products like Eylea and Dupixent against evolving challenges in the regulatory and operational landscape. Stay tuned to discover how investors can monitor these ongoing shifts and remain informed as Regeneron's story...
Intellia Therapeutics Provides Update on MAGNITUDE Clinical Trials of Nexiguran Ziclumeran (nex-z)
27.10.2025 11:30
Conference call today at 8:30 a.m. ETCAMBRIDGE, Mass., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced that the company has temporarily paused patient dosing and screening for its MAGNITUDE and MAGNITUDE-2 Phase 3 clinical trials of nex-z for patients with transthyretin amyloidosis with cardiomyopathy (ATTR-CM) and polyneuropathy (ATTR-PN), r
OncoNano Medicine Presents First-in-Human Data Demonstrating Safety and Early Signs of Clinical Activity of ONM-501, a Dual-Acting STING Agonist, at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
27.10.2025 11:00
DALLAS, October 27, 2025--OncoNano Medicine, Inc. ("OncoNano") announced encouraging first-in-human results from Part 1 of its Phase 1 ON-5001 trial evaluating ONM-501, a dual-acting STING agonist, as monotherapy and in combination with Libtayo® (cemiplimab), Regeneron’s PD-1 inhibitor, in patients with advanced solid tumors and lymphomas. The findings were shared during a poster presentation at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston, M
A Look at Regeneron Pharmaceuticals’s Valuation Following Key European Regulatory Win for Libtayo
27.10.2025 04:17
Regeneron Pharmaceuticals (REGN) just moved a step closer to expanding its cancer therapy portfolio in Europe after the European Medicines Agency’s committee issued a positive opinion for Libtayo as an adjuvant treatment for certain skin cancer patients. See our latest analysis for Regeneron Pharmaceuticals. This regulatory progress adds to a busy stretch for Regeneron, which recently presented at the ESMO Congress and has continued ramping up share repurchases according to major...
Regeneron Earnings: What To Look For From REGN
27.10.2025 03:13
Biotech company Regeneron (NASDAQ:REGN) will be announcing earnings results this Tuesday before market open. Here’s what you need to know.
Earnings Preview: Regeneron (REGN) Q3 Earnings Expected to Decline
21.10.2025 14:00
Regeneron (REGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
REGN Reports Encouraging Data on Gene Therapy for Genetic Hearing Loss (Revised)
16.10.2025 06:54
Regeneron's DB-OTO gene therapy shows hearing gains in nearly all CHORD study participants, with durable and meaningful improvements.
Libtayo® (cemiplimab-rwlc) Approved in the U.S. as First and Only Immunotherapy for Adjuvant Treatment of Cutaneous Squamous Cell Carcinoma (CSCC) with a High Risk of Recurrence After Surgery and Radiation
08.10.2025 18:31
Approval based on pivotal Phase 3 C-POST trial showing Libtayo significantly reduced the risk of disease recurrence or death by 68% compared to placebo (hazard ratio: 0.32; 95% confidence interval: 0.20-0.51; p<0.0001), the primary endpoint of the trial Libtayo is the current standard of care in advanced CSCC; approval has the potential to change the treatment paradigm for patients in an earlier setting TARRYTOWN, N.Y., Oct. 08, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: R
Regeneron Pharmaceuticals Inc. (REGN) Reports Positive Results from Several Late-Stage Trials
02.10.2025 00:10
Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) is one of the 12 Best Widow and Orphan Stocks to Buy According to Analysts. On September 17, 2025, Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) reported positive results from several late-stage trials, highlighting the strength of its pipeline beyond its core ophthalmology franchise. In its Phase 2 COURAGE obesity trial, the combination of […]
Iron Overload Syndrome Market Report 2025-2035, Profiles of Chiesi Group, Novartis, PHARMACOSMOS, Protagonist Therapeutics, Regeneron Pharmaceuticals
01.10.2025 09:43
Iron overload syndrome, including hereditary hemochromatosis, is a disorder marked by excessive iron buildup in the body, primarily due to HFE gene mutations or secondary causes like chronic transfusions. Early diagnosis using serum ferritin and genetic testing is crucial to prevent irreversible damage to organs like the liver and heart. Treatments such as therapeutic phlebotomy, iron chelation, and lifestyle changes effectively manage iron levels. The global market is growing due to improved di
Regeneron’s Evkeeza Receives FDA Approval to Treat HoFH in Children Aged 1 to Less Than 5
01.10.2025 06:16
Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) is one of the best NASDAQ stocks to buy according to hedge funds. On September 26, Evkeeza (evinacumab-dgnb), an ANGPTL3 antibody developed by Regeneron Pharmaceuticals, received an extended indication approval from the US FDA for the treatment of children from age 1 to less than 5 years old with homozygous familial […]
4D Molecular Therapeutics: This Gene Therapy Company May Soon Surprise Investors
30.09.2025 05:08
4D Molecular Therapeutics (FDMT) offers attractive growth potential with strong cash reserves and promising late-stage gene therapy programs. See more here.
Here’s Why Regeneron Pharmaceuticals (REGN) Fell in Q2
29.09.2025 14:43
Chautauqua Capital Management, a division of Baird Asset Management, is a boutique investment firm that released its second quarter 2025 investor letter for the “Baird Chautauqua International and Global Growth Fund”. A copy of the letter can be downloaded here. Global equity markets experienced a significant shift during the quarter, moving from notable losses to reaching […]
FDA Approves Label Extension of REGN's Cholesterol Drug Evkeeza
29.09.2025 12:28
Regeneron wins FDA approval to extend Evkeeza use in children as young as one with severe familial hypercholesterolemia.
Regeneron’s Evkeeza gains FDA approval for young HoFH patients
29.09.2025 10:02
The decision to broaden the antibody’s indication was based on clinical efficacy and safety data from six children.
1 Healthcare Stock with Exciting Potential and 2 We Ignore
29.09.2025 04:36
Personal health and wellness is one of the many secular tailwinds for healthcare companies. But speed bumps such as inventory destockings have persisted in the wake of COVID-19, limiting growth. This has capped the upside for healthcare stocks lately as the industry’s flat return over the past six months has trailed the S&P 500’s 18.3% gain.